Hypertensive vaccine HJY-ATRQ-001 has been accepted as a national first-class biological innovative drug.Recently, the National Drug Administration (NMPA) officially accepted the clinical trial application for the hypertension vaccine HJY-ATRQ-001, marking an important step in my country's treatment

Fragile X syndrome (FXS) small molecule oral medication transactions reach $450 millionRecently, the pharmaceutical industry ushered in a major deal, with a biopharmaceutical company reaching a global exclusive license agreement for small molecule oral medications for Fragile X Syndrome (FXS) for US

Ionis Pharmaceuticals candidate ION582 has been recognized as a breakthrough therapy for the treatment of angel syndromeRecently, Ionis Pharmaceuticals announced that its drug candidate ION582 has been awarded the Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for th

"Duchenne Muscular Dystrophy Multidisciplinary Management Guide (2025 Edition)" ReleaseRecently, the International Association for Neuromuscular Diseases (INMD) and experts from many countries around the world jointly released the "Guidelines for the Management of Multidisciplinary Duchenne Muscular